Not a good acquisition for Gilead, way too risky, expensive and . . . curative. It is clinically risky because CART has severe side effects (including deaths) and commercially risky because of the complex logistics and pricing. $12B for $0 sales now and a hope of $1B in 2020 - that is hugely expensive. Gilead needs top- and bottom-line at this time. Kite offers neither. Kite's CART may be curative, exciting but see what it did to Gilead's market cap. Repeat that failure? Gilead has to buy BioMarin next - no risk, hugely profitable and growing, palliative chronic therapy!
Yes. May be true. However, based upon Gilead's historical pricing models, that should take 12-15 patient therapies to make the deal profitable. Pres Trump is watching you. Proceed with caution.
Just curious what Gilead has done in the past with the commercial organization of the acquired company? Kite's current footprint is small and selective geographically. Will those people be kept and allowed to blend in?
Really? Analysts come on here to pump for information? Here's a thought, call your local Gilead rep or ask a former Gilead who now works for Kite. BTW Gilead is a smart company with great reps and most people are very happy here.
"clinically risky??" Stop talking out of your ass. Do you know anything about these patients? ALL: 4 mo median survival....DLBCL: 6 mo median survival. 1/100 deadly SAEs is sure as shit a risk I'd take when standard of care is death.
Who are you kidding - "most people are happy here?' Remember when most ONC reps left almost 2 years ago?! Gilead Still doesn't get what it takes to be TRUE Oncology company. Most reps are miserable and can't stand their micro managers that came from other divisions with no oncology experience.
